UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Clinical infectious diseases, 2020-09, Vol.71 (6), p.1379-1389

2020

Link zum Volltext

Verfügbarkeit prüfen

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Clinical infectious diseases, 2021-07, Vol.73 (2), p.e485-e493

2021

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Clinical infectious diseases, 2017-07, Vol.65 (1), p.6-12

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

Clinical infectious diseases, 2016-12, Vol.63 (11), p.1405-1411

2016

Link zum Volltext

Verfügbarkeit prüfen

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

Clinical infectious diseases, 2021-06, Vol.72 (11), p.e815-e824

2021

Link zum Volltext

Verfügbarkeit prüfen

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Clinical infectious diseases, 2018-08, Vol.67 (6), p.934-940

2018

Link zum Volltext

Verfügbarkeit prüfen

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies

Clinical infectious diseases, 2017-01, Vol.64 (1), p.44-52

2017

Link zum Volltext

Verfügbarkeit prüfen

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

Clinical infectious diseases, 2016-11, Vol.63 (9), p.1202-1204

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Clinical infectious diseases, 2016-12, Vol.63 (11), p.1479-1481

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease

Clinical infectious diseases, 2017-09, Vol.65 (5), p.864-866

2017

Link zum Volltext

Verfügbarkeit prüfen

Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C

Clinical infectious diseases, 2017-04, Vol.64 (8), p.1035-1042

2017

Link zum Volltext

Verfügbarkeit prüfen

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Clinical infectious diseases, 2019-07, Vol.69 (3), p.514-522

2019

Link zum Volltext

Verfügbarkeit prüfen

Reply to Ozaras et al

Clinical infectious diseases, 2017-05, Vol.64 (10), p.1463-1463

2017

Link zum Volltext

Verfügbarkeit prüfen

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

Clinical infectious diseases, 2017-07, Vol.65 (1), p.13-19

2017

Link zum Volltext

Verfügbarkeit prüfen

Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies

Clinical infectious diseases, 2016-10, Vol.64 (1), p.44-52

2016

Link zum Volltext

Verfügbarkeit prüfen

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1

Clinical infectious diseases, 2016-08, p.ciw507

2016

Link zum Volltext

Verfügbarkeit prüfen

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

Clinical infectious diseases, 2014-12, Vol.59 (12), p.1666-1674

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieClinical Infectious Diseases

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Oxford University Press Journals Current
(20)
Oxford Journals 2020 Medicine
(20)
EZB Electronic Journals Library
(20)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(20)
Standalone journals
(20)
JSTOR All Journals
(18)
MEDLINE
(11)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease

Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Reply to Ozaras et al

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study

Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies

No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection: Table 1

Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

Aktive Filter

Suchergebnisse filtern